Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.
Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Area Under Curve
Cohort Studies
Drug Combinations
Female
Fluorouracil
/ administration & dosage
Glomerular Filtration Rate
/ drug effects
Humans
Male
Middle Aged
Nausea
/ chemically induced
Oxonic Acid
/ administration & dosage
Renal Insufficiency
/ complications
Stomach Neoplasms
/ complications
Tegafur
/ administration & dosage
CDHP
5-fluorouracil
S-1
clearance
eGFR
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
02
07
2018
revised:
11
03
2019
accepted:
28
03
2019
pubmed:
17
4
2019
medline:
25
6
2019
entrez:
17
4
2019
Statut:
ppublish
Résumé
Although dose reduction of S-1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5-fluorouracil, 5-chloro-2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S-1 in patients with renal impairment. We classified patients receiving S-1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S-1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m
Identifiants
pubmed: 30989775
doi: 10.1111/cas.14025
pmc: PMC6550132
doi:
Substances chimiques
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1987-1994Subventions
Organisme : Ministry of Health, Labour and Welfare
ID : 23-A-16
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Cancer Res. 1996 Jun 1;56(11):2602-6
pubmed: 8653704
Jpn J Clin Oncol. 2013 Mar;43(3):271-7
pubmed: 23329851
Clin Cancer Res. 1999 Aug;5(8):2000-5
pubmed: 10473078
Gastric Cancer. 2005;8(1):6-11
pubmed: 15747168
Cancer Chemother Pharmacol. 2016 Feb;77(2):281-8
pubmed: 26791871
Cancer Chemother Pharmacol. 2002 Jul;50(1):25-32
pubmed: 12111108
Kidney Int. 2011 Dec;80(11):1122-37
pubmed: 21918498
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
J Am Soc Nephrol. 1995 Aug;6(2):257-63
pubmed: 7579093
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
Cancer Res. 1993 Sep 1;53(17):4004-9
pubmed: 7689420
Ann Oncol. 2009 May;20(5):946-9
pubmed: 19150953
J Nucl Med. 1998 Dec;39(12):2131-7
pubmed: 9867156
Am J Kidney Dis. 2014 Sep;64(3):411-24
pubmed: 24840668
Cancer Sci. 2019 Jun;110(6):1987-1994
pubmed: 30989775
Anticancer Drugs. 1996 Jul;7(5):548-57
pubmed: 8862723
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Nephron. 1976;16(1):31-41
pubmed: 1244564
Kidney Int. 1985 Nov;28(5):830-8
pubmed: 2418254
Cancer Sci. 2008 May;99(5):1049-54
pubmed: 18380793
Gastric Cancer. 2016 Jul;19(3):876-86
pubmed: 26304171
J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):95-104
pubmed: 9140762
Oncology. 2012;83(1):38-44
pubmed: 22722580